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Abstract: Higher fibre intakes are associated with risk reduction for chronic diseases. This study
investigated the effects of supplementation with PolyGlycopleX® (PGX), a complexed polysaccharide,
on insulin, glucose and lipids in overweight and obese individuals. In this double-blind 12 months
study, participants were randomised into three groups: control (rice flour); PGX or psyllium (PSY).
Participants followed their usual lifestyle and diet but consumed 5 g of their supplement before
meals. Insulin was significantly lower in the PGX and PSY groups compared to control at 3 and 6
months and in the PSY group compared to control at 12 months. Serum glucose was significantly
lower in the PGX group at 3 months compared to control. Total cholesterol was significantly lower in
the PGX and PSY groups compared to control at 3 and 6 months. High density lipoprotein (HDL)
cholesterol was significantly increased in the PGX group compared to control at 12 months. low
density lipoprotein (LDL) cholesterol was significantly lower in the PGX group at 3 and 6 months
compared to control and in the PSY group at 3 months compared to control. A simple strategy of fibre
supplementation may offer an effective solution to glucose, insulin and lipid management without
the need for other nutrient modification.
Keywords: obesity; PGX; psyllium; cholesterol; insulin
1. Introduction
Previous studies have consistently shown that higher fibre intakes are correlated with lower body
weight, body mass index (BMI), waist circumference [1,2] and improved plasma lipid profiles [3–12],
glycaemia and insulinaemia [13], indicating benefits and risk reduction for metabolic syndrome,
cardiovascular disease (CVD) and type 2 diabetes.
While the benefits of a high fibre diet are well known, increasing fruit and vegetable intake to
meet the recommended intake of fibre is difficult for many [14]. Present estimations of dietary fibre
intake in Australian, Canadian, European and American adults is approximately 15–25 g/day [3,15],
which is below the current recommendations for adults in Australia, Canada, Europe and the USA
of 25–30 g/day [16]. Therefore, fibre supplements can provide a cost effective and easy alternative
method for increasing the fibre content of a diet without the need for other major nutrient modifications.
PolyGlycopleX (PGX) has been shown to have lipid lowering effects in healthy subjects [17] as
well as in overweight and obese adults [18]. In a clinical trial with healthy subjects, 25 males and
29 females, mean age of 31.6 ± 10.5 years entered the study [17] and consumed 2.5 g of PGX twice
a day as part of two main meals (breakfast and/or lunch, and/or dinner) for the first seven days,
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followed by 5 g PGX for the last 14 days of the study. The control product was a skimmed milk
powder. PGX’s effects on decreasing total and low density lipoprotein (LDL) cholesterol levels in the
study concur with similar reports in the literature [19]. Studies are required to investigate if these
benefits are sustainable over a longer duration and also in those who are overweight/obese. Another
study with 29 overweight and obese adults, ages 20–65 with a BMI between 25–36 kg/m2, consuming
5 g of PGX in 500 mL of water 5–10 min before each meal, 2–3 times a day for 14 days showed a
significant reduction of total cholesterol (TC) and LDL levels of 19% and 25% respectively, compared to
baseline [18]. However, the supplement was combined with advice for healthy eating, weight loss and
exercise so it is difficult to evaluate the effect of the fibre alone on lipids. This was not a randomised
controlled trial as there was no control group in this study. Recent human studies have shown that
the addition of 2.5 to 5 g of PGX with a meal is highly effective in reducing postprandial glycaemia,
lowering the glycaemic index of food [20] and modifying satiety hormones in healthy adults [21].
However, these studies have some limitations; they were acute or short term, mostly conducted in
healthy, normal weight participants or combined with lifestyle changes.
Psyllium has been evaluated in various human studies for effects on glucose and insulin
homeostasis, body weight, body composition and appetite as well as lipids and lipoproteins [22–30].
Psyllium was reviewed in 2012 for its effect on metabolic syndrome [31]. The authors concluded
that “Collectively, research to date does support the notion that the consumption of psyllium may
provide benefits to many components of the metabolic syndrome”. Psyllium fibre decreased fat
absorption in overweight and obese men, but had no effect on postprandial glucose and insulin
concentrations [32]. In another study, simply adding a psyllium fibre supplement to a normal diet
(10.2 g/day) was sufficient to see improvements in TC and LDL cholesterol but not fasting glucose
or insulin concentrations when compared to the control group [22]. However, a meta-analysis [33]
found that in type 2 diabetes patients, psyllium fibre significantly improved fasting blood glucose,
proportional to loss of glycaemic control.
Apart from these few studies, limited research is available on the effect of PGX fibre on blood
insulin, glucose and lipids. Randomised controlled clinical trials are required to verify whether PGX
can be used for improving insulin, glucose and lipids in the long term and whether this fibre type is
better than other soluble fibres, such as psyllium. Therefore the aim of this study was to investigate
the effect of PGX on insulin, glucose and lipid concentrations. Given the effect of PGX on total and
LDL cholesterol in healthy weight participants and its considerably higher viscosity, we hypothesise
that PGX will have a greater health outcome than psyllium in overweight and obese individuals.
2. Materials and Methods
2.1. Subjects
Overweight and obese individuals with a body mass index (BMI) between 25–47 kg/m2 and
aged between 19 and 68 years, were recruited from the community in Perth, Australia (via newspaper
and radio). Potential participants were screened by telephone or online questionnaire and attended
Curtin University to assess suitability for the study, at which time the details of the study were
explained. Exclusion criteria included smoking, lipid lowering medication, use of steroids and
other agents that may influence lipid metabolism, use of warfarin, diabetes mellitus, hypo- and
hyperthyroidism, cardiovascular events within the last 6 months, psychological unsuitability, major
systemic diseases, gastrointestinal problems, proteinuria, liver, renal failure, weight fluctuations
over the past 6 months, vegetarianism and participation in any other clinical trials within the last
6 months. This study was approved by and conducted in accordance with the ethical standards
of Curtin Human Research Ethics Committee. Written consent was obtained from all participants.
ANZCTR number: ACTRN12611000415909.
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2.2. Study Design
This study is part of a larger trial, which was a randomised, double blind, parallel design study
over a 52 week period. Study participants were randomised by the trial sponsors using a Web site
(http://www.randomization.com) to one of the three groups (three randomly permuted blocks): the
control group who consumed the placebo with their usual diet; the psyllium supplement group (PSY)
who consumed a psyllium supplement with their usual diet and a PGX supplement group (PGX) who
consumed a PGX supplement with their usual diet. Psyllium is a soluble fibre and PolyGlycopleX (PGX)
is a novel, highly viscous functional non-starch polysaccharide complex, with developing viscosity,
manufactured from konjac (glucomannan), sodium alginate and xanthan gum by a proprietary process
(EnviroSimplex®). The fibre supplementation consisted of either 5 g of psyllium (a proprietary
psyllium product with the trade name PgxSyl™) (InovoBiologic, Inc., Calgary, AB, Canada) or 5 g of
PGX (InovoBiologic, Inc., Calgary, AB, Canada). Placebo consisted of 5 g rice flour. All supplements
were artificially sweetened and flavoured. The rice flour provided an appropriate placebo due to
its low energy and fibre content and similarity in texture and appearance to the psyllium and PGX
supplement. Participants were instructed to take either 5 g of the fibre supplements or placebo, mixed
with a minimum of 250 mL water followed by a further 250 mL water, three times daily, 5–10 min
before breakfast, lunch and dinner. Extra water was allowed to be taken ad libitum during or after the
meal if desired and subjects were encouraged to do this. The supplement packages (control, PGX and
psyllium) were from a single batch provided by the manufacturer, and appeared identical so that the
research assistants and participants were blinded to the type of supplement being consumed. Packages
consisted of 5 g doses of the control, PGX or psyllium and were only marked by the participant ID, with
the group allocation only known to the trial sponsors to ensure blinding. Quantities of rice flour and
psyllium were determined by input, with the amounts weighed and checked by the dispensing and
blending department while PGX was analysed according to USP Monograph FCC9 3rd Sup 2015 [34].
All identifiable information from participants was coded to ensure privacy.
The subjects attended a briefing session on how to consume the supplement, complete food
records and comply with the study protocol as previously reported [35]. Briefly, the dietary intake over
the course of the trial was monitored through the completion of 3-day food diaries at baseline, 12, 26
and 52 weeks. All participants in the control and the fibre supplement groups were asked to maintain
their usual dietary intake for the duration of the study. To monitor compliance, all participants were
required to complete a diary to record their supplement consumption and asked to return both the
empty and unused sachets of the supplements at their visits.
2.3. Anthropometry and Body Composition
Measures of body weight, height, waist and hip circumference were undertaken at baseline,
3, 6 and 12 months. Body weight (HBF-514, Omron, Kyoto, Japan) was recorded in light clothing
without shoes. Height was measured to the nearest 0.1 cm using a stadiometer without shoes. Waist
circumference was measured in the standing position at the narrowest area between the lateral lower
rib and the iliac crest. Hip measurement was taken at the largest circumference of the lower abdomen.
2.4. Diet and Physical Activity
Participants completed 3-day food and drink diaries at baseline, 3, 6 and 12 months to monitor for
changes in food intake. Data were analysed with Foodworks 7 Professional (Xyris Software, Brisbane,
Australia), based on data from the AUSNUT database. Participants also completed the International
Physical Activity Questionnaire (IPAQ) at the same time points.
2.5. Measurements of Lipids, Glucose and Insulin Levels
Participants attended clinical rooms at Curtin University Bentley, after a 10–12 h fast, for baseline
measurements. Fasting blood samples (20 mL) were drawn by venipuncture. The collection of fasting
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blood samples was repeated at 3, 6 and 12 months. Serum tubes were allowed to clot and blood
samples were centrifuged at 2500 rpm at 4 ◦C for 10 min using a Hettich Rottina 48R centrifuge. Serum
and plasma were then aliquoted and samples stored at −80 ◦C and analysed after study completion.
Serum triglyceride and total cholesterol was measured by enzymatic colorimetric kits (TRACE
Scientific Ltd., Melbourne, Australia). Serum HDL cholesterol was determined after precipitation of
apoB (apolipoprotein B)-containing lipoproteins with phosphotungstic acid and MgCl2 (magnesium
chloride); the supernatant containing the HDL cholesterol was determined by enzymatic colorimetry
(TRACE Scientific Ltd., Melbourne, Australia). Serum LDL cholesterol was determined by using the
Friedewald equation [36]. Non-esterified fatty acid (NEFA) was determined using WAKO NEFA C kit
(Osaka, Japan). ApoB was analysed using an ELISA kit obtained from Mabtech AB (Nacka Strand,
Stockholm, Sweden).
Plasma glucose concentrations were measured using the Randox glucose GOD-PAP kit (Antrim,
UK), according to the manufacturer’s instructions. Plasma insulin was measured by an ELISA
kit (Alpha Diagnostics International, San Antonio, TX, USA). HOMA2-IR (homeostasis model
assessment of insulin resistance) was used to assess insulin resistance from fasting glucose and
insulin concentrations using a computer model [37].
2.6. Statistical Analysis
A sample size of 24 subjects per group was predicted to provide sufficient power (80%) to detect
a 3% difference in weight before and after treatment within a group. We recruited a total of 53 subjects
per group to accommodate for 50% dropouts. Calculations were based on an average mean weight of
80 kg and a standard deviation of 5% within a group on all eligible subjects. Statistical analysis was
undertaken using SPSS 22 for Windows (SPSS Inc., Chicago, IL, USA). Data were expressed as mean
(±SD or SEM) and assessed for normality to ensure that the assumptions of the analysis were met.
Baseline differences between groups were analysed with one-way ANOVA. The data were analysed
using general linear models with baseline value covariates. If significant between–groups effects were
present, post hoc comparisons between the treatment groups was made using the least significant
difference (LSD) method. Statistical significance was considered at p < 0.05. Intention–to–treat analysis
was also carried out with missing data replaced with the last observation carried forward.
3. Results
3.1. Participants
The 159 participants (19 to 68 years) who met the eligibility criteria were randomised to one of
three groups (Control, PSY, PGX) by assignment of an ID number and the corresponding numbered
supplement. Participant flow through the study can be seen in Figure 1. Although the PGX group
had the highest attrition rate, it was generally due to factors unrelated to the study. A total of
127 participants (54 male, 73 female) completed at least 3 months of the study and were included in the
analysis (45 in Control (24 male), 43 in PSY (15 male) and 39 in PGX (15 male)). Thirty-two participants
withdrew before 3 months and were excluded from analysis due to non-compliance, unrelated
health issues, minor adverse effects and personal reasons. A total of 108 participants at 6 months
(38 in Control, 39 in PSY and 31 in PGX) and 93 participants at 12 months (32 in Control, 36 in PSY and
25 in PGX) were analysed. Results for intention–to–treat analysis for the primary outcome variables
can be found in supplementary files.






  Control (n = 45) PSY (n = 43) PGX (n = 39)  p 
Gender (Male/Female)  24/21  15/28  15/24   
Age (year)  49.82 ± 11.75  49.93 ± 11.04  47.87 ± 12.08   
Height (cm)  171.68 ± 10.04  169.16 ± 10.52  169.76 ± 10.51   
Weight (kg)  94.69 ± 17.05  91.17 ± 14.74  96.24 ± 18.02  0.365
BMI (kg/m2)  32.01 ± 4.2  31.74 ± 3.22  33.25 ± 4.3  0.189
Waist (cm)  103.12 ± 11.02  101.17 ± 9.76  105.97 ± 12.72  0.154
Hip (cm)  112.87 ± 9.04  114.63 ± 8.63  115.71 ± 9.37  0.414
Waist Hip Ratio  0.91 ± 0.08  0.88 ± 0.08  0.92 ± 0.1  0.158
TC (mmol/L)  5 ± 0.85  4.93 ± 1.06  5.02 ± 0.85  0.904
HDL (mmol/L)  1.33 ± 0.37  1.36 ± 0.38  1.28 ± 0.26  0.563
LDL (mmol/L)  3.02 ± 0.87  3.04 ± 0.96  3.2 ± 0.77  0.592
TG (mmol/L)  1.44 ± 1.12  1.18 ± 0.67  1.2 ± 0.56  0.269
Insulin (μIU/mL)  6.11 ± 1.43  5.87 ± 1.64  6.56 ± 1.94  0.172
Glucose (mmol/L)  4.94 ± 0.73  4.79 ± 0.52  4.99 ± 0.56  0.302
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3.2. Baseline Characteristics
There were no significant diffe ences at baseline betwee groups for major characteristics, energy
intake, fibre intake, lipids, insulin or glucose (Table 1).
Table 1. Baseline characteristics.
Control (n = 45) PSY (n = 43) PGX (n = 39) p
Gender (Male/Female) 24/21 15/28 15/24
Age (year) 49.82 ± 11.75 49.93 ± 11.04 47.87 ± 12.08
Height (cm) 171.68 ± 10.04 169.16 ± 10.52 169.76 ± 10.51
Weight (kg) 94.69 ± 17.05 91.17 14.74 96.24 ± 18.02 0.365
BMI (kg/m2) 32.01 ± 4.2 31.74 3.22 33.2 ± 4.3 0.189
Waist (cm) 103.12 ± 11.02 101.17 ± 9.76 105.97 ± 12.72 0.154
Hip (cm) 112.87 ± 9.04 114.63 ± 8.63 115.71 ± 9.37 0.414
Waist Hip Ratio 0.91 ± 0.08 0.88 ± 0.08 0.92 ± 0.1 0.158
TC (mmol/L) 5 ± 0.85 4.93 ± 1.06 5.02 ± 0.85 0.904
HDL ( mol/L) 1.33 ± 0.37 1.36 0.38 1.28 ± 0.26 0.563
LDL (mmol/L) 3. 2 ± 0.87 3.04 .96 3.2 ± 0.77 0.592
TG (mmol/L) 1.44 ± 1.12 1.18 ± 0.67 1.2 ± 0.56 0.269
Insulin (µIU/mL) 6.11 ± 1.43 5.87 ± 1.64 6.56 ± 1.94 0.172
Glucose (mmol/L) 4.94 ± 0.73 4.79 ± 0.52 4.99 ± 0.56 0.302
Values are mean ± SD. PSY (Psyllium), PGX (PolyGlycopleX), TC (Total Cholesterol), TG (Triglyceride). p values are
differences between groups.
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3.3. Diet
The dietary analysis can be seen in Table 2. When examining differences between groups, energy
intake was significantly lower compared to control at 3 months and 6 months in the PGX and PSY
groups and at 12 months only the PGX group demonstrated significantly lower energy intake compared
to the control. Carbohydrate intake was significantly lower at 3 months and 6 months in the PGX and
PSY groups compared to control. Fat intake and protein intake were significantly lower compared to
control at 3 months in the PGX and PSY groups and at 6 months in the PGX group compared to control.
Table 2. Dietary intake during 12 months of fibre supplementation.
Variable 3 Months n P 6 Months n P 12 Months n p
Energy
(kJ/day)
CTR 9013.1 ± 223.6 a 39 0.641 8803.3 ± 282.9 a 34 0.928 8218 ± 295.4 a 31 0.111
PSY 7272.3 ± 218 b 41 <0.001 7539.2 ± 278.8 b 35 <0.001 7657.1 ± 277.9 a,b 35 0.001
PGX 7556.3 ± 243.1 b 33 0.001 7453.7 ± 323.5 b 26 0.009 7315.3 ± 342.4 b 23 0.012
CHO
(g/day)
CTR 212.6 ± 7.7 a 39 0.827 213.4 ± 10 a 34 0.787 200.5 ± 8.4 31 0.212
PSY 181 ± 7.5 b 41 0.002 164.7 ± 9.8 b 35 0.002 183.9 ± 7.9 35 0.015
PGX 175.3 ± 8.4 b 33 0.003 177.2 ± 11.4 b 26 0.032 176.3 ± 9.7 23 0.012
Fat
(g/day)
CTR 83.8 ± 3.2 a 39 0.907 82.3 ± 4.3 a 34 0.887 73 ± 4 31 0.066
PSY 66.9 ± 3.1 b 41 <0.001 72.9 ± 4.2 a,b 35 0.147 73 ± 3.8 35 0.070




CTR 24.2 ±1.2 a 39 0.599 22.1 ± 1 a 34 0.790 21.6 ± 1.3 a 31 0.613
PSY 36.4 ± 1.2 b 41 <0.001 35.1 ± 0.9 b 35 <0.001 36.6 ± 1.3 b 35 <0.001
PGX 36.6 ± 1.3 b 33 <0.001 34.1 ± 1.1 b 26 <0.001 36.1 ± 1.6 b 23 <0.001
Values are mean ± SEM with baseline as a covariate. Different letters in superscript represent significant differences
between groups p < 0.05. p Values are within group differences compared to baseline. CHO (carbohydrate),
CTR (control), PGX (PolyGlycopleX), PSY (psyllium).
3.4. Physical Activity
Physical activity levels did not significantly change from baseline within any groups and there
were no significant differences between groups at any time point (Table 3).
Table 3. Physical activity during 12 months of fibre supplementation.
3 Months MeanChange n P 6 Months
Mean
Change n P 12 Months
Mean
Change n p
CTR 2802.4 ± 449.3 −130.5 29 0.837 2868.2 ± 454.7 −141.2 32 0.823 3294.5 ± 525.6 415.4 30 0.569
PSY 2933 ± 443.6 620.8 30 0.345 3009.3 ± 433.2 187 35 0.876 2879.1 ± 497.8 609.6 33 0.526
PGX 2181.7 ± 470.6 751.3 27 0.254 2681.1 ± 495.5 328.2 27 0.711 2684.9 ± 619.1 194.3 22 0.886
Values are mean kJ/day ± SEM with baseline as a covariate. Mean change from baseline. p Values are within group
differences compared to baseline.
3.5. Lipids
Total cholesterol was significantly lower in the PGX group at 3 months (−8%, p < 0.001) and
6 months (−5.1%, p = 0.048) compared to baseline, as shown in Figure 2A. Total cholesterol was
significantly lower in the PSY group at 3 months (−6.5%, p < 0.001) and 6 months (−4.8%, p = 0.006)
compared to baseline. Total cholesterol was significantly lower at 3 months in the PGX (−8.2%,
p < 0.001) and PSY (−7%, p = 0.001) groups and at 6 months in the PGX (−5.5%, p = 0.047) and PSY
(−5.3%, p = 0.042) groups compared to control. There were no significant differences in total cholesterol
between PSY and PGX groups at 3, 6 or 12 months.





















Figure  2.  Changes  in  fasting  blood  lipids  during  12 months  of  fibre  supplementation  (a)  Total 
Cholesterol; (b) high density lipoprotein (HDL); (c) low density lipoprotein (LDL); (d) Triglyceride; 
(e) NEFA (non‐esterified fatty acid). Values are mean ± 95% CI with baseline as a covariate. * indicates 
within  group  differences  compared  to  baseline. Different  letters  represent  significant  differences 
between groups p < 0.05. 
  
Figure 2. Changes in fasting blood lipids during 12 onths of fibre supple entation (a) Total
Cholesterol; (b) high density lipoprotein ( L); (c) lo density lipoprotein (L L); (d) Triglyceride;
(e) EFA (non-esterified fatty acid). Values are mean ± 95 CI ith baseline as a covariate. * indicates
ithin group differences co pared to baseline. ifferent letters represent significant differences
bet een gro s p 0.05.
High density lipoprotein (HDL) cholesterol was significantly lower in the PSY group at 3 months
(−5.5%, p = 0.022) compared to baseline, as shown in Figure 2B. HDL was significantly higher at
12 months in the PGX group (11.5%, p = 0.019) compared to control. There were no significant
differences in HDL between control and PSY or between PSY and PGX groups at 3, 6 or 12 months.
LDL was significantly lower in the PGX group at 3 months (−13.7%, p < 0.001) and 6 months
(−9.1%, p = 0.006) compared to baseline, shown in Figure 2C. LDL cholesterol was significantly lower
in the PSY group at 3 months (−7.8%, p = 0.002) compared to baseline. LDL was significantly lower
compared to control at 3 months in the PGX (−13.9%, p < 0.001) and PSY (−8.1%, p = 0.007) groups
and at 6 months in the PGX (−11%, p = 0.006) group compared to control. There were no significant
differences in LDL between PSY and PGX groups at 3, 6 or 12 months.
Triglyceride was significantly lower in the control group at 6 months (−7.6%, p = 0.033) compared
to baseline (Figure 2D). TG was significantly lower in the PSY group at 6 months (−12.7%, p = 0.023)
compared to baseline.
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Non-esterified fatty acid (NEFA) was significantly lower in the PSY group at 12 months (−9.5%,
p = 0.021) compared to baseline, as shown in Figure 2E. NEFA was significantly higher in the PGX
group at 3 months (15.7%, p = 0.009) compared to baseline. NEFA was significantly higher in the PGX
group compared to control (16.9%, p = 0.027) and PSY (18.2%, p = 0.017) at 3 months. There were no
significant differences in NEFA between control and PSY at 3, 6 or 12 months.
ApoB did not significantly change within any of the study groups. There were no significant
differences in apoB between control, PSY or PGX groups at 3, 6 or 12 months (data not shown).
3.6. Insulin
Insulin was significantly lower in the PGX group at 3 months (−7.6%, p < 0.001) compared to
baseline (Figure 3A). Insulin was significantly lower in the PSY group at 3 months (−5.5%, p = 0.032)
compared to baseline. Insulin was significantly lower compared to control at 3 months in the PGX
(−9%, p = 0.008) and PSY (−9.4%, p = 0.004) groups, at 6 months in PGX (−9.8%, p = 0.038) and PSY
(−9.1%, p = 0.040) groups compared to control and at 12 months in the PSY group (−9.4%, p = 0.029)
compared to control. There were no significant differences in insulin between PSY and PGX groups at



































Figure 3. Changes in fasting blood para eters during 12 onths of fibre supple entation (a) Insulin,
(b) lucose; (c) 2-IR. Values are ean 95 CI ith baseline as a covariate. * indicates ithin
group differences co pared to baseline. ifferent letters represent significant differences bet een
gro s p 0.05.
3.7. Glucose
Glucose was significantly lower in the PGX group at 6 months (−3.9%, p = 0.033) compared to
baseline, while the decrease at 3 months did not reach significance (−3.4%, p = 0.053) (Figure 3B).
Glucose was significantly lower compared to control at 3 months in the PGX (−4.8%, p = 0.019) group.
There were no significant differences in glucose between control and PSY or between PSY and PGX
groups at 3, 6 or 12 months.
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3.8. Homeostasis Model Assessment of Insulin Resistance
The HOMA2-IR score was significantly lower in the PGX group at 3 months (−9%, p = 0.001) and
6 months (−7.3%, p = 0.039) compared to baseline (Figure 3C). HOMA2-IR was significantly lower in
the PSY group at 3 months (−7%, p = 0.011) and 6 months (−6.7%, p = 0.037) compared to baseline.
HOMA2-IR was significantly lower compared to control at 3 months in the PGX (−10.8%, p = 0.005)
and PSY (−10.8%, p = 0.001) groups, at 6 months in PGX (−11.9%, p = 0.033) and PSY (−11.9%,
p = 0.018) groups compared to control and at 12 months in the PSY group (−11%, p = 0.011) compared
to control. There was a trend for HOMA2-IR to be lower in the PGX group compared to control at
12 months but this was not significant (−8.5%, p = 0.068). There were no significant differences in
HOMA2-IR score between PSY and PGX groups at 3, 6 or 12 months.
3.9. Adverse Events
Minor adverse events were gastrointestinal related (e.g., flatulence, diarrhoea) with four withdrawing
from the study, two in the PGX group and two in the control group. The PSY supplement was better
tolerated and participants did not report any adverse effects.
4. Discussion
Previous epidemiological and cohort studies have consistently revealed that higher fibre intakes
are correlated with lower body weight, BMI, waist circumference [1,2], and improved plasma lipid
profiles [3–12], glycaemia and insulinaemia [13], indicating the benefits and risk reduction for the
metabolic syndrome, CVD and type 2 diabetes. Given that individuals find it difficult to eat the required
amounts of fibre by increasing fruit and vegetable intake, it was hypothesised that fibre supplements
can provide similar health benefits compared with increased dietary fibre intake. Therefore, this study
investigated the effects of 15 g of PGX or psyllium compared to control (rice flour) supplementation
for one year on lipids, insulin and glucose. Specifically, both the PGX and PSY groups demonstrated
significant reductions at 3 months in fasting concentrations of total cholesterol by 8.2% and 7%
respectively, LDL cholesterol by 13.9% and 8.1% respectively, insulin by 9% and 9.4% respectively and
HOMA2-IR score by 11.9%, compared to control group. Only the PGX intervention improved fasting
glucose and HDL cholesterol during the study.
Our results herein are supported by recent human and animal studies which suggest that psyllium
fibre supplementation may provide cardiovascular benefits [22,31]. The effect of PGX on decreasing
total and LDL cholesterol levels in this study concurs with similar reports in the literature describing
the effects of viscous dietary fibre on lowering serum cholesterol levels. Carabin et al. [17] conducted
a clinical trial with healthy subjects, 25 males and 29 females, mean age of 31.6 ± 10.5 years who
consumed 2.5 g of PGX packaged with cereal and yoghurt twice a day as part of two main meals
(breakfast and/or lunch, and/or dinner), for the first seven days, followed by 5 g PGX twice a day for
the last 14 days of the study. The control product was a skimmed milk powder. Investigators observed
significantly lower total and LDL cholesterol in the test group compared to the control group at day 8
(9.4% vs. 3.3% for total and 10.4% vs. 2.5% for LDL cholesterol, respectively) and at day 22 (14.1% vs.
8.3% for total and 16.6% vs. 8.2% for LDL cholesterol, respectively). The differences between groups
was similar to the magnitude observed in our study. Reimer et al. [38] observed the effects of 14 weeks
of short-term PGX supplementation in adults with abdominal obesity and also observed significant
reductions in total and LDL cholesterol. In a pre-post study by Lyon & Reichert [18], 29 overweight
and obese adults with a BMI between 25–36 kg/m2, consumed 5 g of PGX in 500 mL of water 5–10 min
before each meal, 2–3 times a day for 14 days and showed a significant reduction of total cholesterol
and LDL cholesterol levels of 19% and 25% respectively, compared to baseline. As the supplement
intervention in this latter study was combined with lifestyle changes, the decreases in cholesterol
levels were greater than those observed in our current study. Although neither of the studies described
above reported changes in HDL after PGX supplementation, we only observed this effect at 12 months,
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indicating a possible long term effect that has not been demonstrated previously. When looking at the
effect of psyllium, another study [22] also found that simply adding a psyllium fibre supplement to
a normal diet (10.2 g/day) was sufficient to see improvements in total cholesterol (−21%) and LDL
cholesterol (−22%) at 12 weeks compared to control. Similar findings for psyllium have also been
reported in various meta-analyses [39].
Animal studies have demonstrated a beneficial effect of PGX supplementation on glucose control
and fasting insulin [40]. While many human studies have examined the short-term postprandial
glucose response to PGX supplementation [20,41,42], few have looked at the long term effects.
Lyon & Reichert [18] assessed changes to fasting insulin and glucose in their study. The PGX and
lifestyle intervention caused a 6.96% reduction in fasting glucose and a 27.26% reduction in fasting
insulin which is in agreement with our PGX intervention findings. Psyllium has been previously
shown to improve glucose and insulin response [31,33]. In a study by Ziai et al. [23], psyllium was
taken in combination with medication and a significant reduction in fasting glucose was observed.
Gibb et al. [33] reported that psyllium improved glycaemic control proportional to loss of glycaemic
control, which may explain why our non-diabetic psyllium group did not demonstrate any significant
improvements to fasting blood glucose concentrations.
Due to its high viscosity, PGX swells in the stomach and increases feelings of fullness [23,42–45].
Psyllium has also been shown to increase fullness [29] but has a far lower viscosity than PGX [18].
This characteristic may have caused participants to decrease their food intake, which then lead to
significant weight loss [46]. The changes to blood lipids and insulin observed are likely due to the
changes in dietary intake and weight loss observed as well as the possible effect of PGX slowing gastric
emptying and absorption of nutrients in the small intestine [47].
When comparing the PGX and PSY groups in the current study, there were no significant
differences between them except for a lower concentration of TG at 3 months in the PSY group
compared to the PGX group. However, when examining differences compared to control, HDL
cholesterol was significantly higher in the PGX group at 12 months but not in the PSY group. LDL
cholesterol was significantly lower in the PGX group at 3 and 6 months compared to control whereas
LDL cholesterol was only significantly lower in the PSY group at 3 months compared to control.
Glucose was significantly lower in the PGX group at 3 months but not in the PSY group. Intent-to-treat
analysis was carried out but the outcome results were no different from the results presented. In this
regard, the PGX group performed better overall than the PSY group and elicited more health benefits
over the 12 months intervention period.
One of the strengths of this study was the duration, with a 12 months intervention period.
Comparable studies have only been conducted for 14 weeks. This allowed us to investigate the long
term effects of the fibre supplements, especially weight maintenance. This was a double-blinded study
and supplements were packed in identical foil sachets. Investigators were not aware which participants
were taking which supplement; however, due to the different characteristics of the supplements,
participants may have been able to guess if they were taking a fibre supplement or the control, which
is a limitation. The intervention was not combined with any other lifestyle modification advice, thus
it would be simple for consumers to incorporate into their lifestyle or there could be added benefits
if the supplements were combined with healthy lifestyle advice. Other study limitations include
the use of a generally healthy population. We did not specifically recruit participants with elevated
lipid, insulin or glucose concentrations which would have limited our ability to detect significant
improvements. The majority of participants were women and hormonal changes over the 12 months
may have impacted on lipids levels.
5. Conclusions
It is thought the high viscosity of PGX caused participants to decrease their food intake, which then
lead to significant weight loss, lipid, insulin, and glucose reductions. Taking a fibre supplement before
meals was a relatively easy task for people to incorporate into their daily routine and would be a simple
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intervention to implement. We observed similar results between PGX and PSY supplements when
compared to the control group, however the PGX supplement was superior in terms of increased HDL
cholesterol and decreased fasting blood glucose. Therefore, regular consumption of a PolyGlycopleX
or a psyllium supplement is a simple and effective method to improve blood lipids, insulin and glucose
control in overweight or obese people and may lead to risk reduction for metabolic syndrome, CVD
and type 2 diabetes.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/2/091/s1,
Table S1: Lipids, Glucose and Insulin levels during 12 months of fibre supplementation (intention to treat analysis).
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